1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar

Ustekinumab, Denosumab And Pertuzumab Biosimilars Progress

 
• By Anju Ghangurde

Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”

Humira Biosimilars Line Up: Does Interchangeability Matter? • Source: Shutterstock

Biocon fielded a range of questions on the upcoming opportunity for its biosimilar to AbbVie’s Humira (adalimumab) at its quarterly earnings discussion, with senior management indicating that interchangeability isn’t likely to be a defining factor to win in the US market.

Shreehas Tambe, CEO and managing director, Biocon Biologics Ltd (BBL), said the firm’s partnered adalimumab biosimilar, sold as Hulio in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By Dean Rudge

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.